{"prompt": "['Trelagliptin-4002', 'Page 44 of 66', 'Version 1.0', 'November 2, 2016', 'considered an adverse event. A complication that resulted from previously planned surgery shall be', 'reported as an adverse event.', 'Non-urgent surgery or treatment:', 'Non-urgent surgery or treatment that does not induce a change in the condition of a study subject', '(cosmetic surgery, etc.) shall not be considered an adverse event; However, it shall be recorded in', 'the source documents. Complications due to a non-urgent surgery shall be reported as an adverse', 'event.', 'The Insufficient clinical response (lack of efficacy):', 'Insufficient clinical response, efficacy, or pharmacological action shall not be recorded as an adverse', 'event. The principal investigator or the investigator shall make the distinction between worsening of', 'a pre-existing condition and lack of therapeutic efficacy.', 'Overdose of the study drug or comparative drug:', 'Overdose of any medication without manifested symptoms shall not be recorded as an adverse event,', 'but the overdose shall be recorded on the \"Overdose\" page of the CRF. Any manifested symptoms', 'shall also be recorded as adverse events on the \"Adverse events\" of the CRF.', '10.1.3 Serious adverse event', 'Of all the unfavorable medical events that develop with administration of a pharmaceutical product', '(including study drug/ or comparative drug) (irrespective of dose), a serious adverse event is an', 'event that:', '1. results in death,', '2. is life threatening*,', '3. requires inpatient hospitalization or prolongation of existing hospitalization,', '4.', 'results in persistent or significant disability/incapacity,', '5.', 'leads to a congenital anomaly/birth defect, or', '6. other medically significant condition: a medically important event that causes a risk to a', 'study subject even if it is not immediately life-threatening and does not result in death or', 'hospitalization, or requires an action or treatment to prevent the results described in 1 to 5', 'above. In addition, points described in the Takeda Medically Significant Adverse Event List', '(Table 10 (a)) are included in this section.', '*', 'The term \"life threatening\" refers to an event in which the study subject was at risk of death at the', 'time of the event; it does not refer to an event that hypothetically might have caused death if it was', 'more severe.', 'CONFIDENTIAL']['Trelagliptin-4002', 'Page 45 of 66', 'Version 1.0', 'November 2, 2016', 'Table 10.a', 'Takeda Medically Significant AE List', 'Acute respiratory failure/acute respiratory', 'Hepatic necrosis', 'distress syndrome (ARDS)', 'Acute hepatic failure', 'Torsades de bointes/ventricular', 'Anaphylactic shock', 'fibrillation/ventricular tachycardia', 'Acute renal failure', 'Malignant hypertension', 'Pulmonary hypertension', 'Convulsive seizure (including convulsion', 'Pulmonary fibrosis (including interstitial', 'and epilepsy)', 'pneumonia)', 'Agranulocytosis', 'Neuroleptic malignant syndrome/ malignant', 'Aplastic anemia', 'hyperpyrexia', 'Toxic epidermal necrolysis/', 'Spontaneous abortion/ stillbirth and fetal death', 'Oculomucocutaneous syndrome', 'Confirmed or suspected transmission of infection', '(Stevens-Johnson syndrome)', 'by a medicinal product', 'Confirmed or suspected endotoxin shock', '10.1.4 Adverse events of special interest (specific adverse events)', 'An AE of Special Interest (AESI) (serious or non-serious) is one of scientific and medical concern', 'specific to the study drug or comparative drug, for which ongoing monitoring and rapid', 'communication by the principal investigator or investigator to Takeda may be appropriate. Such', 'events may require further investigation in order to establish assessment, and instructions provided', 'to investigators on how and when they should be reported to the sponsor are described in Section', '10.2.1.3.', '10.1.5 Severity of adverse events', 'The severity of adverse events shall be classified and defined as shown below.', 'Mild', 'The event is transient and easily tolerated by the subject.', 'Moderate', \"The event interrupts the subject's usual activities.\", 'Severe', \"The event causes considerable interference with the subject's usual activities.\", '10.1.6 Causality of adverse events', 'The causal relationship of each adverse event to the study drug or comparative drug shall be', 'classified and defined as shown below.', 'An adverse event that follows a temporal sequence (including clinical course after', 'Related', 'discontinuation), or an adverse event in which there is at least a reasonable', 'CONFIDENTIAL']['Trelagliptin-4002', 'Page 46 of 66', 'Version 1.0', 'November 2, 2016', 'probability that a causal relationship to the study drug or comparative drug cannot be', 'ruled out, although other factors such as underlying disease, complications, or', 'concomitant drugs/treatment are also suspected.', 'An adverse event that does not follow a temporal sequence from administration of', 'Not', 'the study drug or comparative drug. Very likely due to other factors such as', 'related', 'underlying disease, complications, or concomitant drugs/treatment.', '10.1.7 Relationship to study procedures', 'The relationship shall be recorded as \"Yes\" if the principal investigator or the investigator considers', 'that there is reasonable possibility that an adverse event is due to a study procedure. Otherwise, the', 'relationship shall be recorded as \"No.\"', '10.1.8 Date of onset', 'The date of onset of adverse event shall be determined according to the following rules:', 'Adverse events', 'Date of onset', 'Signs, symptoms, diseases', 'The date on which the first signs/symptoms were noted by the', '(diagnoses)', 'study subject and/or the principal investigator or investigator.', 'The date on which a diagnosis was confirmed through a test(s).', 'The date on which a diagnosis was confirmed, even when the', 'Asymptomatic diseases', 'test results indicate an old sign(s) of the disease or an', 'approximate time of its onset.', 'The date on which the first worsening of diseases/symptoms was', 'Exacerbation of complications', 'noted by the study subject and/or the principal investigator or', 'investigator.', 'Onset of a test abnormality', 'after the start of study drug', 'The date on which a clinically significant laboratory abnormality', 'administration or comparative', 'was detected.', 'drug administration', 'Worsening of a baseline test', 'abnormality after the start of', 'The date on which a clear increase/decrease in a laboratory', 'study drug administration or', 'parameter was clinically confirmed based on the time profile of', 'comparative drug', 'the parameter.', 'administration', '10.1.9 Date of resolution', 'The date of resolution of an adverse event is the date on which the study subject recovered', '(including resolution with sequelae). If a study subject died due to the adverse event concerned, it', 'CONFIDENTIAL']['Trelagliptin-4002', 'Page 47 of 66', 'Version 1.0', 'November 2, 2016', 'shall be the date of death. The adverse event shall be recorded as \"ongoing\" if the study subject has', 'not yet recovered by the end of the study.', '10.1.10 Actions taken for the study drug or comparative drug', 'Actions taken for the study drug or comparative drug shall be classified or defined as shown below.', 'The study drug or comparative drug is discontinued because of an adverse', 'event (including withdrawal by the study subject at his/her own discretion).', 'Drug withdrawn', 'When the study is discontinued but administration of the study drug or', 'comparative drug is still continued, the classification should be \"Dose not', 'changed.\"', 'The dose was not changed after the onset of the adverse event.', 'Dose not', 'The study drug or comparative drug was discontinued, reduced, or increased', 'because of another adverse event.', 'changed', 'The study drug was discontinued or reduced for a reason other than the', 'adverse event, e.g., inadvertence of the study subject.', 'Unknown', 'It has not been possible to determine what action has been taken because the', 'study subject is lost to follow-up.', 'The administration of the study drug or comparative drug had already been', 'Not Applicable', 'completed or discontinued before the onset of the adverse event.', 'Dose reduced', 'The dose of the study drug or comparative drug is reduced because of an adverse', 'event (including dose reduction by the study subject at his/her own discretion).', 'The dose of the study drug or comparative drug was increased because of the', 'Dose increased', 'adverse event (including dose increase by the study subject at his/her own', 'discretion).', 'If administration of the study drug or comparative drug is suspended (i.e.,', 'Washout', 'interrupted) (including suspension/interruption by the study subject at his/her own', 'discretion) because of the adverse event but resumed thereafter, shall be defined', 'as \"washout\".', '10.1.11 Outcome', 'Outcome of adverse events is classified as follows:', 'Category', 'Criteria', 'Recovered', '- Disappearance or recovery of symptoms and findings', '- Laboratory values returned to normal or baseline', '- The intensity is lowered by one or more stages', '- Symptoms or findings mostly disappeared', 'Improved', '-', 'Laboratory values improved, but have not returned to normal or baseline', '- The study subject died from a cause other than the concerned adverse event', 'while the condition was resolving (recording of the date of death unnecessary)', 'CONFIDENTIAL']", "completion": ""}